drugset / Trial / NCT00236457

A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

NCT00236457

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to document both short-term, as well as long-term efficacy and safety of a long-acting injectable formulation of risperidone, in comparison with olanzapine for the treatment of patients with schizophrenia or schizoaffective disorder.

Timeline

Start
2000-11
Primary completion
Completion
2002-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 25 mg Intramuscular
Subject Risperidone Other / unclassified 50 mg Intramuscular

Indications